Suppr超能文献

WIP 缺乏症的表型和治疗:文献综述及 1 例移植前连续供者淋巴细胞输注以清除 CMV 的患者回顾

The Phenotype and Treatment of WIP Deficiency: Literature Synopsis and Review of a Patient With Pre-transplant Serial Donor Lymphocyte Infusions to Eliminate CMV.

机构信息

Division of Pediatric Hematology-Oncology, Department of Pediatrics and Adolescent Medicine, Medical University Graz, Graz, Austria.

Pediatric Intensive Care Unit, Division of General Pediatrics, Department of Pediatrics and Adolescent Medicine, Medical University Graz, Graz, Austria.

出版信息

Front Immunol. 2018 Nov 2;9:2554. doi: 10.3389/fimmu.2018.02554. eCollection 2018.

Abstract

Early diagnosis of primary immunodeficiency disorders (PID) is vital and allows directed treatment, especially in syndromes with severe or profound combined immunodeficiency. In PID patients with perinatal CMV or other opportunistic, invasive infections (e.g., or ), multi-organ morbidity may already arise within the first months of life, before hematopoietic stem cell transplantation (HSCT) or gene therapy can be undertaken, compromising the definitive treatment and outcome. Deficiency of Wiskott-Aldrich syndrome (WAS) protein-interacting protein (WIP deficiency) causes an autosomal recessive, WAS-like syndrome with early-onset combined immunodeficiency that has been described in three pedigrees to date. While WAS typically includes combined immunodeficiency, microthrombocytopenia, and eczema, the clinical and laboratory phenotypes of WIP-deficient patients-including lymphocyte subsets, platelets, lymphocyte proliferation , and IgE-varied widely and did not entirely recapitulate WAS, impeding early diagnosis in the reported patients. To elucidate the phenotype of WIP deficiency, we provide a comprehensive synopsis of clinical and laboratory features of all hitherto-described patients ( = 6) and WIP negative mice. Furthermore, we summarize the treatment modalities and outcomes of these patients and review in detail the course of one of them who was successfully treated with serial, unconditioned, maternal, HLA-identical donor lymphocyte infusions (DLI) against life-threatening, invasive CMV infection, followed by a TCRαβ/CD19-depleted, treosulfan/melphalan-conditioned, peripheral blood HSCT and repetitive, secondary-prophylactic, CMV-specific DLI with 1-year post-HSCT follow-up. This strategy could be useful in other patients with substantial premorbidity, considered "," who have an HLA-identical family donor, to eliminate infections and bridge until definitive treatment.

摘要

原发性免疫缺陷病(PID)的早期诊断至关重要,可以进行针对性治疗,尤其是在伴有严重或严重联合免疫缺陷的综合征中。在围产期巨细胞病毒(CMV)或其他机会性、侵袭性感染(如,,)的 PID 患者中,多器官发病率可能在造血干细胞移植(HSCT)或基因治疗之前的生命最初几个月内出现,从而影响到确定性治疗和结局。威特综合征蛋白相互作用蛋白(WIP)缺陷导致常染色体隐性遗传、WAS 样综合征,伴有早发性联合免疫缺陷,迄今为止已在三个家系中描述。虽然 WAS 通常包括联合免疫缺陷、微小血小板减少症和湿疹,但 WIP 缺陷患者的临床和实验室表型——包括淋巴细胞亚群、血小板、淋巴细胞增殖和 IgE——差异很大,并不完全再现 WAS,这在报告的患者中阻碍了早期诊断。为了阐明 WIP 缺陷的表型,我们全面总结了所有先前描述的患者(= 6)和 WIP 阴性小鼠的临床和实验室特征。此外,我们总结了这些患者的治疗方式和结果,并详细回顾了其中一名患者的病程,该患者成功接受了针对危及生命的侵袭性 CMV 感染的连续、非条件、母体、HLA 匹配供体淋巴细胞输注(DLI)治疗,随后进行了 TCRαβ/CD19 耗竭、三氟尿苷/马法兰预处理、外周血 HSCT 以及反复、二级预防性、CMV 特异性 DLI 治疗,随访至 HSCT 后 1 年。对于有大量前期疾病且被认为是“高危”的其他患者,这种策略可能有用,他们有 HLA 匹配的家族供体,可以消除感染并为确定性治疗搭桥。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7682/6224452/320dcf6e52b2/fimmu-09-02554-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验